Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

NCT05991895 is registered in ClinicalTrials.gov with Jinming Yu as lead sponsor.

NCT NCT05991895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05991895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer
Lead sponsor
Jinming Yu
Phase
Observational
Overall status
Unknown status
Start date
July 24, 2023
Completion date
July 31, 2026
Enrollment
5,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)